Abstract 798: Pathway-directed high-throughput drug screen identifies PI3K inhibitors that synergistically potentiate antitumor activity of HDAC inhibitors in cutaneous T-cell lymphoma. Read more about Abstract 798: Pathway-directed high-throughput drug screen identifies PI3K inhibitors that synergistically potentiate antitumor activity of HDAC inhibitors in cutaneous T-cell lymphoma.
Abstract 1957: Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Read more about Abstract 1957: Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.
Abstract 2812: Status of TGFbeta signaling determines PARP inhibitor sensitivity in head and neck cancer. Read more about Abstract 2812: Status of TGFbeta signaling determines PARP inhibitor sensitivity in head and neck cancer.
Abstract 93: Transcriptional control of glucocorticoid responses in leukemia. Read more about Abstract 93: Transcriptional control of glucocorticoid responses in leukemia.
Abstract 388: Pathway-directed high throughput drug screen identifies PI3K inhibitors that synergistically potentiate anti-tumor activity of HDAC inhibitors in mycosis fungoides and Sézary syndrome. Read more about Abstract 388: Pathway-directed high throughput drug screen identifies PI3K inhibitors that synergistically potentiate anti-tumor activity of HDAC inhibitors in mycosis fungoides and Sézary syndrome.
Abstract 1205: HER3 is a functional molecular target in HPV-associated head and neck cancer. Read more about Abstract 1205: HER3 is a functional molecular target in HPV-associated head and neck cancer.
Abstract 243: Investigating microtubule growth dynamics in patient-derived metastatic prostate cancer cells. Read more about Abstract 243: Investigating microtubule growth dynamics in patient-derived metastatic prostate cancer cells.
Abstract 2608: Ibrutinib significantly improves survival in a human Burkitt lymphoma (BL) xenograft NSG mouse model: Ibrutinib may be a potential adjuvant agent in the treatment of BL. Read more about Abstract 2608: Ibrutinib significantly improves survival in a human Burkitt lymphoma (BL) xenograft NSG mouse model: Ibrutinib may be a potential adjuvant agent in the treatment of BL.
Abstract 760: On the evolution of erlotinib-resistant NSCLC subpopulations. Read more about Abstract 760: On the evolution of erlotinib-resistant NSCLC subpopulations.
Abstract LB-235: IL10 autoregulatory loop in DLBCLs: New biomarker and a therapeutic target. Read more about Abstract LB-235: IL10 autoregulatory loop in DLBCLs: New biomarker and a therapeutic target.
